Actively Recruiting
Evaluation of TAK-226 for Anemia in Japanese Adults with Lower-Risk Myelodysplastic Syndromes in an Open-Label Study
Led by Takeda · Updated on 2026-10-28
42
Participants Needed
21
Research Sites
237 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TAK-226 to see how it may improve symptoms of transfusion-dependent anemia in Japanese adults diagnosed with lower-risk myelodysplastic syndromes MDS. This Phase 2 study focuses on patients classified as very low, low, or intermediate risk according to established criteria. The study aims to assess the efficacy and safety of TAK-226, an investigational drug given by injection. During the Treatment Period, participants receive TAK-226 as a subcutaneous injection every four weeks for about one year. The study includes a Screening Period lasting up to six weeks, followed by a Safety Follow-Up Period of eight weeks after treatment ends. There is also a Long-Term Follow-Up Period lasting approximately five years from the first dose to monitor any lasting effects or side effects. Participants will visit the clinic approximately every two to four weeks during treatment. Researchers will measure outcomes such as the percentage of participants achieving transfusion independence or increases in hemoglobin levels over specific timeframes. In addition, various blood tests and safety assessments will be conducted throughout the study and follow-up periods. The total participation duration may last up to about six years.
CONDITIONS
Brief Title
A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here